LucilleAFerranteMD

Pediatric Hematology & Oncology • Huntsville, AL

Medical Director- Oncology/ Janssen Scientific Affairs

Join to view full profile

Dr. Ferrante is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ferrante's full profile

Already have an account?

Office
101 Sivley Rd SW
Huntsville, AL 35801
Phone+1 256-265-5833

Fax+1 256-265-5834

Education & Training

Medical University of South CarolinaFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Tulane UniversityResidency, Pediatrics, 1998 - 2001
University of South Alabama College of MedicineClass of 1998

Certifications & Licensure

AL State Medical License 2000 - 2025
NC State Medical License 2021 - 2025
SC State Medical License 2003 - 2025
PA State Medical License 2013 - 2024
MD State Medical License 2009 - 2018
LA State Medical License 1999 - 2001

Publications & Presentations

PubMed

51 citations
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, po...
Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing
The Lancet. Haematology. 2019-07-01
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma:
Peter Martin, Andre Goy, Radhakrishnan Ramchandren, Lucille Ferrante, Anil Londhe
Journal of Oncology Pharmacy Practice. 2019-02-20

Lectures

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018